Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG [ID6454]

  • Awaiting development
  • GID-TA11592
  • Expected publication date: TBC

28717-Sasanlimab-Bacillus-Calmette-Guerin-for-Bladder-Cancer-V1.0-APR2024-NON-CONF.pdf (nihr.ac.uk)